Brion D E, Murrieta D, Job J C
Horm Res. 1985;22(1-2):107-9. doi: 10.1159/000180081.
34 adolescents referred for excessive height prediction (HP) (11 boys with HP greater than 196 cm, 23 girls with HP greater than 180 cm) were treated for 9-15 months with bromocriptine (5-7.5 mg/day). Minor and transient side effects were observed in 20% of the subjects at the beginning of the treatment. Treatment had to be stopped in 1 boy complaining of asthenia and headache. Puberty developed normally, 19 girls experienced menarche during treatment and 1 continued regular menses. Bromocriptine treatment induced: (1) a significant decrease (p less than 0.001) in growth velocity from (mean +/- SEM) 8.6 +/- 0.4 to 5.3 +/- 1.5 cm/year in boys and from 7.1 +/- 0.2 to 4.6 +/- 0.6 cm/year in girls; (2) a twofold mean increase in skeletal maturation rate. Adult HP was reduced significantly from 202 +/- 1.4 to 195.4 +/- 1.2 cm in boys, and from 184 +/- 0.7 to 179.8 +/- 0.7 in girls. These results confirm our previous report suggesting that bromocriptine is a valuable alternative to sex steroid treatment in order to limit the final height in excessively tall adolescents.
34名因预测身高过高（HP）而前来就诊的青少年（11名男孩，预测身高超过196厘米；23名女孩，预测身高超过180厘米）接受了9至15个月的溴隐亭治疗（5 - 7.5毫克/天）。治疗开始时，20%的受试者出现轻微且短暂的副作用。1名主诉乏力和头痛的男孩不得不停止治疗。青春期发育正常，19名女孩在治疗期间月经初潮，1名女孩月经持续规律。溴隐亭治疗导致：（1）男孩的生长速度显著下降（p < 0.001），从（均值±标准误）8.6±0.4厘米/年降至5.3±1.5厘米/年，女孩从7.1±0.2厘米/年降至4.6±0.6厘米/年；（2）骨骼成熟率平均提高两倍。男孩的成人预测身高从202±1.4厘米显著降至195.4±1.2厘米，女孩从184±0.7厘米降至179.8±0.7厘米。这些结果证实了我们之前的报告，表明溴隐亭是性类固醇治疗的一种有价值的替代方法，可用于限制过高青少年的最终身高。
